AHA/ASA Science Advisory Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
نویسنده
چکیده
Karen L. Furie, MD, MPH, FAHA, Co-Chair; Larry B. Goldstein, MD, FAAN, FAHA, Co-Chair; Gregory W. Albers, MD; Pooja Khatri, MD, MSc, FAHA; Ron Neyens, PharmD, BCPS; Mintu P. Turakhia, MD, MAS; Tanya N. Turan, MD, MS, FAHA; Kathryn A. Wood, RN, PhD; on behalf of the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease
منابع مشابه
Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association.
The rate of stroke among adults with atrial fibrillation (AF) varies widely, ranging between 1% and 20% annually (mean 4.5% per year) depending on comorbidities and a patient’s history of prior cerebrovascular events. Stratification of stroke risk is important, because the major risk of antithrombotic medications used to lower the incidence of AFrelated stroke is bleeding. For warfarin, this in...
متن کاملAHA/ASA publish advisory on oral antithrombotics for stroke prevention in nonvalvular artial fibrillation.
www.aafp.org/afp Volume 87, Number 10 ◆ May 15, 2013 Among adults with atrial fibrillation, the annual rate of stroke ranges from 1 to 20 percent, depending on comorbidities and the patient’s history of cerebrovascular events. Because of the risk of bleeding associated with antithrombotics such as warfarin (Coumadin) that are used to reduce the incidence of atrial fibrillation–related stroke, i...
متن کاملAn evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS2 or CHA2DS2-VASc scoring systems. Those at intermediate-to-high risk have traditionally been treated with therapeutic anticoagulation with warfarin f...
متن کاملAntithrombotic therapy for stroke prevention in atrial fibrillation.
Atrial fibrillation (AF) is the most potent common risk factor for ischemic stroke. The number of Americans with nonvalvular AF is expected to increase markedly over the next several decades, making AF-related stroke an important public health concern. Given the individual and societal burden associated with AF-related stroke, efforts to identify and implement efficacious and acceptably safe th...
متن کاملDesign and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
BACKGROUND Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting 1% to 2% of the population and raising the risk of stroke 5-fold. Until recently, the only treatment choices for stroke prevention in patients with AF have been vitamin K antagonists (VKA) or antiplatelet drugs. With approval of novel oral anticoagulants (NOACs) antithrombotic treatment, patterns are changing. ...
متن کامل